Conatumumab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Template:Infobox drug/mab source |
| Target | TRAIL-R2 (CD262) |
| Identifiers | |
| CAS Number | 896731-82-1 |
| ATC code | none |
| Synonyms | anti-TRAIL receptor 2 monoclonal antibody, AMG 655 |
| Chemical data | |
| Formula | C6466H10006N1730O2024S40 |
| Molar mass | 145.65 kDa[[Script error: No such module "String".]] |
Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[1][2]
The drug was developed by Amgen Inc.
Clinical trials
It will be included in the forthcoming I-SPY2 breast cancer trial.[3]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
- ↑ National Cancer Institute: Definition of conatumomab
- ↑ http://www.reuters.com/article/idUSN1612347120100317 "Breast cancer study aims to speed drugs, cooperation" March 2010
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Amgen
- Pages with broken file links
- Monoclonal antibody stubs
